Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | TAR DNA binding protein | Starlite/ChEMBL | No references |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Schistosoma mansoni | thyroid hormone receptor | 0.0132 | 0.1899 | 0.1918 |
Mycobacterium leprae | PROBABLE ACETOLACTATE SYNTHASE (LARGE SUBUNIT) ILVB (ACETOHYDROXY-ACID SYNTHASE) | 0.043 | 1 | 1 |
Trypanosoma brucei | phosphonopyruvate decarboxylase-like protein, putative | 0.0139 | 0.208 | 0.5 |
Trypanosoma brucei | phosphonopyruvate decarboxylase-like protein, putative | 0.0139 | 0.208 | 0.5 |
Mycobacterium ulcerans | acetolactate synthase | 0.0246 | 0.4994 | 0.4994 |
Loa Loa (eye worm) | thiamine pyrophosphate enzyme | 0.0246 | 0.5006 | 0.9245 |
Mycobacterium ulcerans | acetolactate synthase large subunit IlvB | 0.0246 | 0.4994 | 0.4994 |
Mycobacterium ulcerans | acetolactate synthase 1 catalytic subunit | 0.043 | 1 | 1 |
Plasmodium vivax | acyl-CoA synthetase, putative | 0.0246 | 0.4994 | 0.5 |
Mycobacterium leprae | Probable Acetolactate synthase IlvG (Acetohydroxy-acid synthase)(ALS) | 0.043 | 1 | 1 |
Echinococcus multilocularis | Mitotic checkpoint protein PRCC, C terminal | 0.0122 | 0.1632 | 0.8238 |
Trypanosoma cruzi | phosphonopyruvate decarboxylase, putative | 0.0139 | 0.208 | 0.5 |
Mycobacterium ulcerans | putative oxalyl-CoA decarboxylase | 0.043 | 1 | 1 |
Schistosoma mansoni | hypothetical protein | 0.0122 | 0.1632 | 0.158 |
Schistosoma mansoni | thyroid hormone receptor | 0.0132 | 0.1899 | 0.1918 |
Treponema pallidum | pyruvate oxidoreductase | 0.0063 | 0 | 0.5 |
Trichomonas vaginalis | set domain proteins, putative | 0.023 | 0.4571 | 1 |
Schistosoma mansoni | acetolactate synthase | 0.0367 | 0.8298 | 1 |
Echinococcus multilocularis | thyroid hormone receptor alpha | 0.0132 | 0.1899 | 1 |
Onchocerca volvulus | 0.023 | 0.4571 | 0.5 | |
Loa Loa (eye worm) | ILVBL protein | 0.026 | 0.5384 | 1 |
Mycobacterium ulcerans | hypothetical protein | 0.043 | 1 | 1 |
Mycobacterium tuberculosis | Acetolactate synthase (large subunit) IlvB1 (acetohydroxy-acid synthase) | 0.0184 | 0.3304 | 0.3304 |
Echinococcus granulosus | Mitotic checkpoint protein PRCC C terminal | 0.0122 | 0.1632 | 1 |
Trypanosoma cruzi | phosphonopyruvate decarboxylase, putative | 0.0139 | 0.208 | 0.5 |
Giardia lamblia | Pyruvate-flavodoxin oxidoreductase | 0.0063 | 0 | 0.5 |
Leishmania major | putative pyruvate/indole-pyruvate carboxylase, putative | 0.0246 | 0.4994 | 1 |
Schistosoma mansoni | acetolactate synthase | 0.0367 | 0.8298 | 1 |
Plasmodium falciparum | acyl-CoA synthetase | 0.0246 | 0.4994 | 0.5 |
Brugia malayi | Pre-SET motif family protein | 0.0202 | 0.3809 | 0.3564 |
Mycobacterium ulcerans | 2-succinyl-5-enolpyruvyl-6-hydroxy-3-cyclohexene-1-carboxylate synthase | 0.0076 | 0.0378 | 0.0378 |
Mycobacterium tuberculosis | Probable acetolactate synthase IlvG (acetohydroxy-acid synthase)(ALS) | 0.043 | 1 | 1 |
Entamoeba histolytica | pyruvate:ferredoxin oxidoreductase | 0.0063 | 0 | 0.5 |
Mycobacterium tuberculosis | Probable oxalyl-CoA decarboxylase OxcA | 0.043 | 1 | 1 |
Mycobacterium ulcerans | hypothetical protein | 0.0139 | 0.208 | 0.208 |
Loa Loa (eye worm) | pre-SET domain-containing protein family protein | 0.0202 | 0.3809 | 0.6853 |
Mycobacterium ulcerans | pyruvate or indole-3-pyruvate decarboxylase Pdc | 0.0246 | 0.4994 | 0.4994 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | 6.3096 uM | PubChem BioAssay. qHTS of TDP-43 Inhibitors. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 28.1838 uM | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of JMJD2A-Tudor Domain. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID504402] | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.